EOLS (Evolus) Non Operating Income: $1.8 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EOLS Evolus Inc EOLS
72 GF Score
Price $9.30
GF Value $13.38
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Evolus Non Operating Income?

Evolus EOLS +2.76% 72 Non Operating Income is $1.8 Mil as of Jun. 2026. GuruFocus rates EOLS with a GF Score™ of 72/100 and a GF Value™ of $13.38 (Possible Value Trap). The stock has 8 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Evolus's Non Operating Income for the three months ended in Jun. 2026 was $-1.0 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $1.8 Mil.

Evolus Non Operating Income Related Terms

Evolus Non Operating Income Historical Data

* Premium members only.

The historical data trend for Evolus's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolus Non Operating Income Chart

Evolus Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.24 -5.76 -3.56 -7.05 4.40

Evolus Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.76 -1.79 4.52 0.13 -1.04
EOLS
72GF Score
Evolus Inc EOLS
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evolus Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $1.8 Mil mean?
Evolus (EOLS) has a Non Operating Income of $1.8 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Evolus and its competitors.
Is Evolus' Non Operating Income too high?
Evolus' current Non Operating Income is $1.8 Mil. Overall, Evolus has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' Non Operating Income compare to AQST and TLRY?
Evolus' Non Operating Income of $1.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Drug Manufacturers company?
A good Non Operating Income depends on the Drug Manufacturers industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Evolus and its competitors. Evolus's current Non Operating Income is $1.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.38, compared to a current price of $9.30 — trading 30.5% below its estimated fair value. The current Non Operating Income is $1.8 Mil. Evolus' overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Evolus (EOLS), the current Non Operating Income is $1.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evolus (EOLS) Overvalued in 2026?

Based on GuruFocus' analysis, Evolus stock appears to be undervalued. The current stock price of $9.30 is trading 30.5% below its estimated GF Value™ of $13.38. GuruFocus considers Evolus to be Possible Value Trap.

Key valuation signals for EOLS:

  • Non Operating Income: $1.8 Mil
  • GF Value™: $13.38 vs. price of $9.30 (30.5% below fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evolus Business Description

Other Exchanges EVL:Germany
Address 520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
72GF Score

Get the complete analysis for EOLS

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.30
Price
$13.38
GF Value